Clinical Research Directory
Browse clinical research sites, groups, and studies.
Neoadjuvant Treatment Modalities in Esophageal Cancer
Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Summary
Esophageal cancer is the most prevalent cancer globally with poor survival outcome. The prognosis with surgery alone is poor, accounting for 30-40% of overall survival at 5 year. Either neoadjuvant chemotherapy (nCT) or chemoradiotherapy (nCRT) has been shown as efficatious therapy to improve patients outcomes in esophageal or esophagogastric junction cancer as compared with surgery alone. The purpose of this study was to explore the optimal neoadjuvant treatment modalities including PD-1/PD-L1 antibody or targeted drug for patients with esophageal or esophagogastric junction cancer.
Official title: Cohort Study of Neoadjuvant Treatment Modalities for Esophageal Cancer
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
2000
Start Date
2002-01-01
Completion Date
2030-12-31
Last Updated
2026-01-21
Healthy Volunteers
No
Conditions
Interventions
Platinum based chemotherapy
q1-3W according to physician's preference
Paclitaxel based chemotherapy
q1-3W according to physician's preference
Radiotherpay
40-50Gy/1.8-2.2Gy/20-25f
Surgery
Radical esophagectomy
Immunotherapy
Anti-PD-1/PD-L1 Antibody
5-FU Analog based chemotherpay
W1-5 qW or d1-14, q3W according to physician's preference
Nimotuzumab
200-400mg, d1,qW
Locations (1)
Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC)
Beijing, China